U.S. markets closed
  • S&P Futures

    3,652.75
    +29.50 (+0.81%)
     
  • Dow Futures

    29,840.00
    +211.00 (+0.71%)
     
  • Nasdaq Futures

    12,388.25
    +111.25 (+0.91%)
     
  • Russell 2000 Futures

    1,840.50
    +20.40 (+1.12%)
     
  • Crude Oil

    45.00
    -0.34 (-0.75%)
     
  • Gold

    1,782.70
    +1.80 (+0.10%)
     
  • Silver

    22.80
    +0.20 (+0.89%)
     
  • EUR/USD

    1.1956
    +0.0021 (+0.18%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3350
    +0.0019 (+0.14%)
     
  • USD/JPY

    104.3740
    +0.0500 (+0.05%)
     
  • BTC-USD

    19,605.44
    +95.56 (+0.49%)
     
  • CMC Crypto 200

    384.82
    +20.23 (+5.55%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,823.68
    +390.06 (+1.48%)
     

Seres Therapeutics to Host First Quarter 2020 Financial Results and Operational Progress Conference Call on May 7, 2020

·1 min read

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on May 7, 2020 at 8:30 a.m. ET to discuss first quarter 2020 results and provide a general business update.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 9143286. To join the live webcast, please visit the "Investors and Media" section of the Seres website at www.serestherapeutics.com.

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma and SER-301 for ulcerative colitis. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200430005117/en/

Contacts

PR Contact
Lisa Raffensperger
lisa@tenbridgecommunications.com

IR Contact
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com